Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;5(2):201-211.
doi: 10.1007/s41030-019-00100-w. Epub 2019 Oct 18.

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis

Rita Sousa  1 , Deepak R Lakha  2 , Sandrine Brette  3 , Simon Hitier  4
Affiliations

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Ambroxol Hard-Boiled Lozenges in Patients with Acute Pharyngitis

Rita Sousa et al. Pulm Ther. 2019 Dec.

Abstract

Introduction: The aim of this study was to evaluate the efficacy and safety of a new hard-boiled lozenge formulation containing ambroxol 20 mg versus placebo for the relief of sore throat in patients with acute pharyngitis.

Methods: This was a phase 3, randomized, double-blind, placebo-controlled, parallel-group multicenter trial conducted between June and September 2018 in South Africa. Patients with a diagnosis of acute pharyngitis, onset ≤ 72 h, and sore throat pain of at least moderate intensity were randomized to receive either ambroxol 20 mg or placebo hard-boiled lozenges. The primary efficacy endpoint was the normalized time-weighted sum of pain intensity differences (SPID) from baseline over 3 h following administration of the first lozenge (SPIDnorm,0-3h). Secondary efficacy endpoints included SPID 24 h after the first lozenge intake (SPIDnorm,0-24h) and patient assessment of efficacy at 3 and 24 h after the first lozenge.

Results: Of 422 patients from 11 centers, 390 were randomized to one of the two treatment groups (n = 196, ambroxol; n = 194, placebo) and 388 were analyzed (modified intention-to-treat). The mean ± standard deviation SPIDnorm,0-3h values were -0.386 (0.259) and -0.366 (0.243) in the ambroxol and placebo groups, respectively, and the adjusted mean ± standard error SPIDnorm0-3h difference between ambroxol and placebo was -0.020 (0.025) (p = 0.443). Comparable results between treatment groups were also found for SPIDnorm,0-24h and patient assessment of efficacy at 3 and 24 h after the first lozenge. The incidence of treatment-emergent adverse events (TEAEs) was similar between treatment groups (11.7% for ambroxol versus 9.3% for placebo).

Conclusion: Although marked pain relief was observed over the first 3 h of treatment, superiority of ambroxol 20 mg hard-boiled lozenges versus placebo was not demonstrated in this study.

Trial registration: NCT03583658.

Funding: Sanofi-Aventis Group.

Keywords: Acute pharyngitis; Ambroxol; Local anesthetic; Lozenges; Sore throat.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. AESI adverse event of special interest, SAE serious adverse event, V visit
Fig. 2
Fig. 2
Patient disposition. mITT modified intention-to-treat
Fig. 3
Fig. 3
Change from baseline in throat pain intensity 3 h after the first lozenge (mITT population). CI confidence interval, LS least square, mITT modified intention-to-treat, SD standard deviation
Fig. 4
Fig. 4
LS mean (SE) for the time course of PID from pre-dose baseline over the first 24 h (mITT population). LS least square, mITT modified intention-to-treat, PID pain intensity difference, SE standard error
Fig. 5
Fig. 5
a Patient assessments of efficacy at 3 and 24 h and b final patient and investigator assessments of efficacy (mITT population). mITT modified intention-to-treat population
See this image and copyright information in PMC

References

    1. Palm J, Fuchs K, Stammer H, Schumacher-Stimpfl A, Milde J. Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha) Int J Clin Pract. 2018;72(12):17. doi: 10.1111/ijcp.13272. - DOI - PMC - PubMed
    1. Fischer J, Pschorn U, Vix JM, Peil H, Aicher B, Muller A, de Mey C. Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat. Randomised, double-blind, placebo-controlled trials regarding the local anaesthetic properties. Arzneimittelforschung. 2002;52(4):256–263. - PubMed
    1. Russo M, Bloch M, de Looze F, Morris C, Shephard A. Flurbiprofen microgranules for relief of sore throat: a randomised, double-blind trial. Br J Gen Pract. 2013;63(607):e149–e155. doi: 10.3399/bjgp13X663118. - DOI - PMC - PubMed
    1. McNally D, Shephard A, Field E. Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection. J Pharm Pharm Sci. 2012;15(2):281–294. doi: 10.18433/J31309. - DOI - PubMed
    1. Bouroubi A, Donazzolo Y, Donath F, Eccles R, Russo M, Harambillet N, Gautier S, Montagne A. Pain relief of sore throat with a new anti-inflammatory throat lozenge, ibuprofen 25 mg: a randomised, double-blind, placebo-controlled, international phase III study. Int J Clin Pract. 2017;71(9):4. doi: 10.1111/ijcp.12961. - DOI - PubMed

Associated data

LinkOut - more resources